CSIMarket
 


Pfizer Inc  (PFE)
Other Ticker:  
 
 

PFE's Revenue Growth by Quarter and Year

Pfizer Inc's Revenue results by quarter and year




PFE Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 14,248.00 24,289.00 23,635.00 11,684.00
III Quarter September 13,232.00 22,638.00 24,094.00 12,131.00
II Quarter June 12,734.00 27,742.00 18,977.00 11,801.00
I Quarter March 18,282.00 25,661.00 14,582.00 12,028.00
FY   58,496.00 100,330.00 81,288.00 47,644.00



PFE Revenue fourth quarter 2023 Y/Y Growth Comment
Pfizer Inc reported fall in Revenue in the fourth quarter 2023 by -41.34% to $ 14,248.00 millions, from the same quarter in 2022.
The drop in the fourth quarter 2023 Pfizer Inc's Revenue compares unfavorably to the Company's average Revenue growth of 4.74%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Revenue growth. While Pfizer Inc' s Revenue drop of -41.34% ranks overall at the positon no. 631 in the fourth quarter 2023.




PFE Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -41.34 % 2.77 % 102.29 % -7.91 %
III Quarter September -41.55 % -6.04 % 98.62 % -4.33 %
II Quarter June -54.1 % 46.19 % 60.81 % -11.03 %
I Quarter March -28.76 % 75.98 % 21.23 % -8.31 %
FY   -41.7 % 23.43 % 70.62 % -7.93 %

Financial Statements
Pfizer Inc's fourth quarter 2023 Revenue $ 14,248.00 millions PFE's Income Statement
Pfizer Inc's fourth quarter 2022 Revenue $ 24,289.00 millions Quarterly PFE's Income Statement
New: More PFE's historic Revenue Growth >>


PFE Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 7.68 % 7.29 % -1.91 % -3.68 %
III Quarter September 3.91 % -18.4 % 26.96 % 2.8 %
II Quarter June -30.35 % 8.11 % 30.14 % -1.89 %
I Quarter March -24.73 % 8.57 % 24.8 % -5.2 %
FY (Year on Year)   -41.7 % 23.43 % 70.62 % -7.93 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #77
Overall #631

Revenue Y/Y Growth Statistics
High Average Low
84.01 % 4.74 % -41.7 %
(Apr 03 2022)   (Dec 31 2023)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #77
Overall #631
Revenue Y/Y Growth Statistics
High Average Low
84.01 % 4.74 % -41.7 %
(Apr 03 2022)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Pfizer Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
42.3 % 0.66 % -30.35 %
(Dec. 30. 2009)  


PFE's IV. Quarter Q/Q Revenue Comment
Pfizer Inc achieved in the IV. Quarter 2023 above company average sequential Revenue increase of 7.68%, to $ 14,248.00 millions, from $13,232.00 millions in the third quarter.
PFE is undergoing a remarkable growth, not just reporting above average increase, and additionally improving rate, Leonora Esposito, Major Pharmaceutical Preparations industry contributor allocated in Rome added.

Within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Pfizer Inc's Revenue growth quarter on quarter, overall rank is 273.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #38
Overall #273
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #38
Overall #273
Revenue Q/Q Growth Statistics
High Average Low
42.3 % 0.66 % -30.35 %
(Dec. 30. 2009)  


PFE's IV. Quarter Q/Q Revenue Comment
Pfizer Inc achieved in the IV. Quarter 2023 above company average sequential Revenue increase of 7.68%, to $ 14,248.00 millions, from $13,232.00 millions in the third quarter.
PFE is going from strength to strength, with recording better then normal growth, but also improving speed.

Within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Pfizer Inc's Revenue growth quarter on quarter, overall rank is 273.


Pfizer Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Oct 01 2023)
12 Months Ending
(Jul 02 2023)
12 Months Ending
(Apr 02 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 58,496.00 $ 68,537.00 $ 77,943.00 $ 92,951.00 $ 100,330.00
Y / Y Revenue Growth (TTM) -41.7 % -31.24 % -22.93 % 0.63 % 23.43 %
Year on Year Revenue Growth Overall Ranking # 133 # 360 # 260 # 200 # 331
Seqeuential Revenue Change (TTM) -14.65 % -12.07 % -16.15 % -7.35 % 0.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 631 # 1825 # 2413 # 1654 # 1163




Cumulative Revenue growth Comment
Pfizer Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -41.7% year on year, at Dec 31 2023 compare to the -31.24% decrease at Oct 01 2023. If the Pfizer Inc's fiscal year would end at Dec 31 2023, annual Revenue would be $58,496 millions.

Within the Healthcare sector 26 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 133, from total ranking in previous quarter at 360.

Revenue TTM Q/Q Growth Statistics
High Average Low
84.01 %
4.74 %
-41.7 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 30
Healthcare Sector # 27
Overall # 133

Revenue TTM Y/Y Growth Statistics
High Average Low
84.01 %
4.74 %
-41.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 77
S&P 500 # 631
Cumulative Revenue growth Comment
Pfizer Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -41.7% year on year, at Dec 31 2023 compare to the -31.24% decrease at Oct 01 2023. If the Pfizer Inc's fiscal year would end at Dec 31 2023, annual Revenue would be $58,496 millions.

Within the Healthcare sector 26 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 133, from total ranking in previous quarter at 360.

Revenue TTM Q/Q Growth Statistics
High Average Low
84.01 %
4.74 %
-41.7 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 30
Healthcare Sector # 27
Overall # 133

Revenue TTM Y/Y Growth Statistics
High Average Low
84.01 %
4.74 %
-41.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 77
S&P 500 # 631




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PFE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for PFE's Competitors
Revenue Growth for Pfizer Inc's Suppliers
Revenue Growth for PFE's Customers

You may also want to know
PFE's Annual Growth Rates PFE's Profitability Ratios PFE's Asset Turnover Ratio PFE's Dividend Growth
PFE's Roe PFE's Valuation Ratios PFE's Financial Strength Ratios PFE's Dividend Payout Ratio
PFE's Roa PFE's Inventory Turnover Ratio PFE's Growth Rates PFE's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
National Research Corporation-0.37%$ -0.375 millions
3m Company-0.82%$ -0.817 millions
Viatris Inc -1.00%$ -0.998 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Baxter International Inc -3.55%$ -3.550 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Abbvie inc -5.42%$ -5.423 millions
Hologic Inc-5.69%$ -5.688 millions
Encision Inc -6.08%$ -6.083 millions
Biogen Inc -6.20%$ -6.199 millions
Curis Inc -6.62%$ -6.616 millions
Bio rad Laboratories Inc -6.62%$ -6.621 millions
Charles River Laboratories International inc -7.85%$ -7.853 millions
Arcus Biosciences Inc -7.89%$ -7.889 millions
Novartis Ag-9.97%$ -9.971 millions
Henry Schein Inc-10.50%$ -10.501 millions
Catalent Inc -10.88%$ -10.879 millions
Masimo Corp-11.06%$ -11.064 millions
Mettler toledo International Inc -11.60%$ -11.600 millions
Integrated Biopharma Inc-14.15%$ -14.150 millions
Aytu Biopharma Inc -15.51%$ -15.510 millions
Precision Optics Corporation Inc -18.05%$ -18.051 millions
Novavax inc-18.48%$ -18.483 millions
Jazz Pharmaceuticals Plc-18.92%$ -18.925 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com